Novartis AG Receivables 2010-2024 | NVS

Novartis AG receivables for the quarter ending June 30, 2024 were $8.480B, a 11.14% decline year-over-year.

  • Novartis AG receivables for 2023 were $7.533B, a 9.61% decline from 2022.
  • Novartis AG receivables for 2022 were $8.334B, a 0.62% increase from 2021.
  • Novartis AG receivables for 2021 were $8.283B, a 2.05% decline from 2020.

Novartis AG Receivables 2010-2024 | NVS

  • Novartis AG receivables for 2023 were $7.533B, a 9.61% decline from 2022.
  • Novartis AG receivables for 2022 were $8.334B, a 0.62% increase from 2021.
  • Novartis AG receivables for 2021 were $8.283B, a 2.05% decline from 2020.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$861.3B
Novo Nordisk (NVO)$592.4B
Johnson & Johnson (JNJ)$402.2B
AbbVie (ABBV)$341.7B
Merck (MRK)$299.6B
AstraZeneca (AZN)$243.5B
Pfizer (PFE)$169B
Sanofi (SNY)$144.1B
Innoviva (INVA)$1.2B